Literature DB >> 21433039

Silibinin mode of action against hepatitis C virus: a controversy yet to be resolved.

Harel Dahari, Jeremie Guedj, Alan S Perelson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21433039      PMCID： PMC3677944          DOI： 10.1002/hep.24310

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  9 in total

Review 1.  A perspective on modelling hepatitis C virus infection.

Authors:  J Guedj; L Rong; H Dahari; A S Perelson
Journal:  J Viral Hepat       Date:  2010-08-15       Impact factor: 3.728

2.  Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin.

Authors:  Michael Biermer; Thomas Berg
Journal:  Gastroenterology       Date:  2009-05-30       Impact factor: 22.682

3.  Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

Authors:  A U Neumann; N P Lam; H Dahari; D R Gretch; T E Wiley; T J Layden; A S Perelson
Journal:  Science       Date:  1998-10-02       Impact factor: 47.728

4.  Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient.

Authors:  B A Payer; T Reiberger; K Rutter; S Beinhardt; A F Staettermayer; M Peck-Radosavljevic; P Ferenci
Journal:  J Clin Virol       Date:  2010-08-14       Impact factor: 3.168

5.  Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.

Authors:  Peter Ferenci; Thomas-Matthias Scherzer; Heidrun Kerschner; Karoline Rutter; Sandra Beinhardt; Harald Hofer; Maximilian Schöniger-Hekele; Heidemarie Holzmann; Petra Steindl-Munda
Journal:  Gastroenterology       Date:  2008-08-03       Impact factor: 22.682

6.  Multiple effects of silymarin on the hepatitis C virus lifecycle.

Authors:  Jessica Wagoner; Amina Negash; Olivia J Kane; Laura E Martinez; Yaakov Nahmias; Nigel Bourne; David M Owen; Joe Grove; Claire Brimacombe; Jane A McKeating; Eve-Isabelle Pécheur; Tyler N Graf; Nicholas H Oberlies; Volker Lohmann; Feng Cao; John E Tavis; Stephen J Polyak
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

7.  RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.

Authors:  Sophie Le Pogam; Amritha Seshaadri; Aren Ewing; Hyunsoon Kang; Alan Kosaka; Jun-Mei Yan; Michelle Berrey; Bill Symonds; Abel De La Rosa; Nick Cammack; Isabel Nájera
Journal:  J Infect Dis       Date:  2010-10-13       Impact factor: 5.226

8.  Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation.

Authors:  Jessica Wagoner; Chihiro Morishima; Tyler N Graf; Nicholas H Oberlies; Elodie Teissier; Eve-Isabelle Pécheur; John E Tavis; Stephen J Polyak
Journal:  PLoS One       Date:  2011-01-28       Impact factor: 3.240

9.  Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase.

Authors:  Abdelhakim Ahmed-Belkacem; Nazim Ahnou; Laetitia Barbotte; Czeslaw Wychowski; Coralie Pallier; Rozenn Brillet; Ralf-Torsten Pohl; Jean-Michel Pawlotsky
Journal:  Gastroenterology       Date:  2009-12-04       Impact factor: 22.682
  9 in total
  6 in total

1.  Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics.

Authors:  Harel Dahari; Shimon Shteingart; Inna Gafanovich; Scott J Cotler; Massimo D'Amato; Ralf T Pohl; Gali Weiss; Yaakov J Ashkenazi; Thomas Tichler; Eran Goldin; Yoav Lurie
Journal:  Liver Int       Date:  2014-10-10       Impact factor: 5.828

2.  Understanding silibinin's modes of action against HCV using viral kinetic modeling.

Authors:  Jeremie Guedj; Harel Dahari; Ralf T Pohl; Peter Ferenci; Alan S Perelson
Journal:  J Hepatol       Date:  2012-01-13       Impact factor: 25.083

Review 3.  Silymarin for HCV infection.

Authors:  Stephen J Polyak; Nicholas H Oberlies; Eve-Isabelle Pécheur; Harel Dahari; Peter Ferenci; Jean-Michel Pawlotsky
Journal:  Antivir Ther       Date:  2012-09-25

4.  Silibinin Induced Human Glioblastoma Cell Apoptosis Concomitant with Autophagy through Simultaneous Inhibition of mTOR and YAP.

Authors:  Zhuan-Li Bai; Vincent Tay; Shu-Zhong Guo; Juan Ren; Mao-Guo Shu
Journal:  Biomed Res Int       Date:  2018-03-26       Impact factor: 3.411

5.  Inhibition of RNA binding to hepatitis C virus RNA-dependent RNA polymerase: a new mechanism for antiviral intervention.

Authors:  Abdelhakim Ahmed-Belkacem; Jean-François Guichou; Rozenn Brillet; Nazim Ahnou; Eva Hernandez; Coralie Pallier; Jean-Michel Pawlotsky
Journal:  Nucleic Acids Res       Date:  2014-07-22       Impact factor: 16.971

6.  A hepatitis C virus infection model with time-varying drug effectiveness: solution and analysis.

Authors:  Jessica M Conway; Alan S Perelson
Journal:  PLoS Comput Biol       Date:  2014-08-07       Impact factor: 4.475
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.